The intracellular signalosome of PD-L1 in cancer cells

被引:207
作者
Escors, David [1 ,2 ]
Gato-Canas, Maria [1 ]
Zuazo, Miren [1 ]
Arasanz, Hugo [1 ,3 ]
Jesus Garcia-Granda, Maria [1 ]
Vera, Ruth [3 ]
Kochan, Grazyna [1 ]
机构
[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain
[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England
[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain
关键词
T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;
D O I
10.1038/s41392-018-0022-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
引用
收藏
页数:9
相关论文
共 113 条
  • [1] IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
    Abiko, K.
    Matsumura, N.
    Hamanishi, J.
    Horikawa, N.
    Murakami, R.
    Yamaguchi, K.
    Yoshioka, Y.
    Baba, T.
    Konishi, I.
    Mandai, M.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1501 - 1509
  • [2] EGFR TKI combination with immunotherapy in non-small cell lung cancer
    Ahn, Myung-Ju
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 465 - 469
  • [3] Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
  • [4] PD1 signal transduction pathways in T cells
    Arasanz, Hugo
    Gato-Canas, Maria
    Zuazo, Miren
    Ibanez-Vea, Maria
    Breckpot, Karine
    Kochan, Grazyna
    Escors, David
    [J]. ONCOTARGET, 2017, 8 (31) : 51936 - 51945
  • [5] Arasanz H, 2017, MELANOMA MANAG, V4, P39, DOI 10.2217/mmt-2016-0019
  • [6] B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
    Azuma, Takeshi
    Yao, Sheng
    Zhu, Gefeng
    Flies, Andrew S.
    Flies, Sarah J.
    Chen, Lieping
    [J]. BLOOD, 2008, 111 (07) : 3635 - 3643
  • [7] Restoring function in exhausted CD8 T cells during chronic viral infection
    Barber, DL
    Wherry, EJ
    Masopust, D
    Zhu, BG
    Allison, JP
    Sharpe, AH
    Freeman, GJ
    Ahmed, R
    [J]. NATURE, 2006, 439 (7077) : 682 - 687
  • [8] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [9] Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
    Blank, C
    Kuball, J
    Voelkl, S
    Wiendl, H
    Becker, B
    Walter, B
    Majdic, O
    Gajewski, TF
    Theobald, M
    Andreesen, R
    Mackensen, A
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) : 317 - 327
  • [10] Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
    Blank, C
    Gajewski, TF
    Mackensen, A
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) : 307 - 314